Novavax COVID-19 vaccine US trial participants considered fully vaccinated two weeks after -CDC dosing

by



[ad_1]

Vials with a sticker saying “COVID-19 / Coronavirus Vaccine / Injection only” and a medical syringe can be seen in front of a Novavax logo displayed in this illustration taken on October 31, 2020. REUTERS / Dado Ruvic / Illustration

Aug. 30 (Reuters) – Participants in Novavax Inc.’s advanced COVID-19 vaccine trial (NVAX.O) can be considered fully vaccinated two weeks after completing their two-dose vaccination schedule, said on Monday. United States Centers for Disease Control and Prevention. .

The CDC said the guidelines do not imply an approval of the shot, which has not yet been cleared for use in the United States. Novavax plans to file an emergency use authorization application in the United States in the fourth quarter of 2021. read more

The guidelines provide clarity for participants in vaccine clinical trials in the United States at a time when more and more employers in the United States are demanding that staff be vaccinated against COVID-19.

Reporting by Carl O’Donnell Editing by Chris Reese

Our Standards: Thomson Reuters Trust Principles.

[ad_2]

Source link